Hanna Nilsson

Hanna Nilsson

Auto-generated profile, based on publicly available information

Hanna Nilsson

Department of Oncology‐Pathology, Laboratory of Translational Fertility Preservation Karolinska Institutet Stockholm Sweden

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2017 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
AZA Zandian
A Zandian
LWL Wingård
L Wingård
HNH Nilsson
H Nilsson
ESEvelina Sjöstedt
Evelina Sjöstedt
DJD X Johansson
D X Johansson
MPM A A Persson
M A A Persson
Immunological and inflammatory reactions have been suggested to have a role in the development of schizophrenia, a hypothesis that has recently been supported by genetic data. The aim of our study was to perform an unbiased search for autoantibodies in patients with a first psychotic episode, and to explore the association between any seroreactivity and the development of a Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) disorder characterized by chronic or relapsing psychotic symptoms. We collected plasma samples from 53 patients when they were treated for their first-episode psychosis, and 41 non-psychotic controls, after which the patients were followed for a mean duration of 7 years. Thirty patients were diagnosed with schizophrenia, delusional disorder, schizoaffective disorder, bipolar disorder or a long-term unspecified nonorganic psychosis during follow-up, whereas 23 patients achieved complete remission. At the end of follow-up, plasma samples were analyzed for IgG reactivity to 2304 fragments of human proteins using a multiplexed affinity proteomic technique. Eight patient samples showed autoreactivity to the N-terminal fragment of the PAGE (P antigen) protein family (PAGE2B/PAGE2/PAGE5), whereas no such autoreactivity was seen among the controls. PAGE autoreactivity was associated with a significantly increased risk of being diagnosed with schizophrenia during follow-up (odds ratio 6.7, relative risk 4.6). An immunohistochemistry analysis using antisera raised against the N-terminal fragment stained an unknown extracellular target in human cortical brain tissue. Our findings suggest that autoreactivity to the N-terminal portion of the PAGE protein family is associated with schizophrenia in a subset of patients with first-episode psychosis.

10 January 2024 in Acta Obstetricia et Gynecologica Scandinavica
Verified
Journal Article
Open access
KRKenny A. Rodriguez-Wallberg
Kenny A. Rodriguez-Wallberg
HNHanna P. Nilsson
Hanna P. Nilsson
EREmelie Bergman Røthe
Emelie Bergman Røthe
AZAllan Zhao
Allan Zhao
PSPrakesh S. Shah
Prakesh S. Shah
GAGanesh Acharya
Ganesh Acharya
Introduction: Available data on severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection and pregnancy outcomes mostly refer to women contracting the infection during advanced pregnancy or close to delivery. There is limited information on the association between SARS‐CoV‐2 infection in early pregnancy and outcomes thereof.Material and methods: We aimed to systematically review the maternal, fetal and neonatal outcomes following SARS‐CoV‐2 infection in early pregnancy, defined as <20 weeks of gestation (PROSPERO Registration 2020 CRD42020177673). Searches were carried out in PubMed, Medline, EMBASE, and Scopus databases from January 2020 until April 2023 and the WHO database of publications on coronavirus disease 2019 (COVID‐19) from December 2019 to April 2023. Cohort and case–control studies on COVID‐19 occurring in early pregnancy that reported data on maternal, fetal, and neonatal outcomes were included. Case reports and studies reporting only exposure to SARS‐CoV‐2 or not stratifying outcomes based on gestational age were excluded. Data were extracted in duplicate. Meta‐analyses were conducted when appropriate, using R meta (R version 4.0.5).Results: A total of 18 studies, 12 retrospective and six prospective, were included in this review, reporting on 10 147 SARS‐CoV‐2‐positive women infected in early pregnancy, 9533 neonates, and 180 882 SARS‐CoV‐2 negative women. The studies had low to moderate risk of bias according to the Newcastle–Ottawa quality assessment Scale. The studies showed significant clinical and methodological heterogeneity. A meta‐analysis could be performed only on the outcome miscarriage rate, with a pooled random effect odds ratio of 1.44 (95% confidence interval 0.96–2.18), showing no statistical difference in miscarriage in SARS‐CoV‐2‐infected women. Individual studies reported increased incidences of stillbirth, low birthweight and preterm birth among neonates born to mothers affected by COVID‐19 in early pregnancy; however, these results were not consistent among all studies.Conclusions: In this comprehensive systematic review of available evidence, we identified no statistically significant adverse association between SARS‐CoV‐2 infection in early pregnancy (before 20 weeks of gestation) and fetal, neonatal, or maternal outcomes. However, a 44% increase in miscarriage rate is concerning and further studies of larger sample size are needed to confirm or refute our findings.

9 December 2023 in BMJ Open
Verified
Journal Article
Open access
PDF file
KRKenny A. Rodriguez-Wallberg
Kenny A. Rodriguez-Wallberg
HNHanna Pauline Nilsson
Hanna Pauline Nilsson
JBJonas Bergh
Jonas Bergh
JMJohan Malmros
Johan Malmros
PLPer Ljungman
Per Ljungman
SESandra Eloranta
Sandra Eloranta
Background Gonadotropin-releasing hormone agonists (GnRHa) cotreatment used to transiently suppress ovarian function during chemotherapy to prevent ovarian damage and preserve female fertility is used globally but efficacy is debated. Most clinical studies investigating a beneficial effect of GnRHa cotreatment on ovarian function have been small, retrospective and uncontrolled. Unblinded randomised studies on women with breast cancer have suggested a beneficial effect, but results are mixed with lack of evidence of improvement in markers of ovarian reserve. Unblinded randomised studies of women with lymphoma have not shown any benefit regarding fertility markers after long-term follow-up and no placebo-controlled study has been conducted so far. The aim of this study is to investigate if administration of GnRHa during cancer treatment can preserve fertility in young female cancer patients in a double-blind, placebo-controlled clinical trial. Methods and analysis A prospective, randomised, double-blinded, placebo-controlled, phase III study including 300 subjects with breast cancer. In addition, 200 subjects with lymphoma, acute leukemias and sarcomas will be recruited. Women aged 14–42 will be randomised 1:1 to treatment with GnRHa (triptorelin) or placebo for the duration of their gonadotoxic chemotherapy. Follow-up until 5 years from end of treatment (EoT). The primary endpoint will be change in anti-Müllerian hormone (AMH) recovery at follow-up 12 months after EoT, relative to AMH levels at EoT, comparing the GnRHa group and the placebo group in women with breast cancer. Ethics and dissemination This study is designed in accordance with the principles of Good Clinical Practice (ICH-GCP E6 (R2)), local regulations (ie, European Directive 2001/20/EC) and the ethical principles of the Declaration of Helsinki. Within 6 months of study completion, the results will be analysed and the study results shall be reported in the EudraCT database. Study registration The National Institutional review board in Sweden dnr:2021–03379, approval date 12 October 2021 (approved amendments 12 June 2022, dnr:2022-02924-02 and 13 December 2022, dnr:2022-05565-02). The Swedish Medical Product Agency 19 January 2022, Dnr:5.1-2021-98927 (approved amendment 4 February 2022). Manufacturing authorisation for authorised medicinal products approved 6 December 2021, Dnr:6.2.1-2020-079580. Stockholm Medical Biobank approved 22 June 2022, RBC dnr:202 253. Trial registration number NCT05328258; EudraCT number:2020-004780-71.

20 November 2024 in Acta Obstetricia et Gynecologica Scandinavica
Verified
Journal Article
Open access
AMAnna Marklund
Anna Marklund
YJYanyu Jiang
Yanyu Jiang
HRHanna Röjlar
Hanna Röjlar
FSFotios Sergouniotis
Fotios Sergouniotis
HNHanna Nilsson
Hanna Nilsson
KRKenny A. Rodriguez-Wallberg
Kenny A. Rodriguez-Wallberg
Introduction: Our objective was to assess the feasibility of fertility preservation (FP) in women referred for cervix cancer, the long‐term reproductive outcome, and overall survival.Material and Methods: Prospective cohort study of patients referred for FP counseling between 1999 and 2021 to the FP program of Karolinska University Hospital, Stockholm, Sweden. Baseline data included age, parity, disease stage, treatment characteristics, and FP methods applied. Data on reproductive outcomes and overall survival (by October 19, 2023) were retrieved from clinical registries and a population‐based register. Trial registration number: ClinicalTrials.gov NTC04602962.Results: In total, 91 women were referred, 67% with stage I cancers and 25%, 7%, and 1% with stages II, III, and IV, respectively. Cancers were diagnosed during pregnancy or postpartum in six cases. Cancer treatments included fertility‐sparing surgery in 14%, hysterectomy in 30%, and radiochemotherapy in 79% of cases. The treatment modality did not rule out the possibility to undergo FP, and following counseling, 68 patients elected to undergo FP by cryopreservation of embryos or oocytes (N = 11), ovarian tissue (N = 54), or both (N = 3). After a mean follow‐up of 8.1 years, 25 women (37%) returned to the center, five women achieved conception either spontaneously or through assisted reproduction, and 11 women became mothers through adoption or surrogacy. In the group of women receiving radical surgery or chemo/radiotherapy, no live births using cryopreserved specimens have yet been achieved. During follow‐up, 7 women (10%) in the FP group and 5 women (24%) in the group without FP had died of their disease. Cancer recurrence was documented in 19 patients.Conclusions: Our findings underscore the complexity and challenges associated with FP in the context of cervix cancer. Results of this study demonstrate that many women diagnosed with cervix cancer at reproductive age desire to achieve parenthood. While fertility‐sparing surgery can allow pregnancy, those who undergo a hysterectomy are limited to adoption, surrogacy, or the emerging possibility of uterus transplantation.

5 March 2026 in The Clinical Respiratory Journal
Verified
Journal Article
Open access
FLFrida E. Lundberg
Frida E. Lundberg
ASAmalie H. Sneckenborg
Amalie H. Sneckenborg
HNHanna Nilsson
Hanna Nilsson
KRKenny A. Rodriguez-Wallberg
Kenny A. Rodriguez-Wallberg
Background: Previous studies have suggested a negative impact of asthma on fertility, and it has been hypothesized that the underlying inflammation is playing an important role. However, available data are scarce and mostly refer to women conceiving naturally. With this study, we wished to investigate whether asthma affects the outcomes of medically assisted reproduction or not. Methods: We conducted a prospective cohort study of 809 women, with ( N = 213) or without asthma ( N = 596), undergoing fertility treatment between 2009 and 2019 at one academic‐based reproductive medicine center. Treatment outcome measures included clinical pregnancy rate (CPR) and live birth rate (LBR) per stimulation cycle, per oocyte pickup, and per embryo transfer, among women undergoing in vitro fertilization treatment, and LBR among women treated by intrauterine insemination. Odds ratios and 95% confidence intervals were estimated using multivariable generalized estimating equation models. Results: No significant differences were found in CPR or LBR between women with asthma and women without asthma undergoing in vitro fertilization ( N = 694) or intrauterine insemination ( N = 45). In women with asthma, the adjusted odds ratio of clinical pregnancy per embryo transfer for all cycles was 0.91 (95% CI, 0.71–1.16), and the adjusted odds ratio of live birth per embryo transfer for all cycles was 0.90 (95% CI, 0.70–1.16). The adjusted odds ratio of live birth per performed intrauterine insemination was 1.42 (95% CI, 0.63–3.21) in women with asthma. Conclusions: Infertile women with asthma undergoing medically assisted reproductive treatment have a similar chance of achieving clinical pregnancy and live childbirth when compared to infertile women without asthma.

19 May 2026 in Human Reproduction Open
Verified
Journal Article
Open access
TLTekla Lind
Tekla Lind
HNHanna P Nilsson
Hanna P Nilsson
MFMikael Andersson Franko
Mikael Andersson Franko
KRKenny A. Rodriguez-Wallberg
Kenny A. Rodriguez-Wallberg
STUDY QUESTION: What is the likelihood of future childbirth in women undergoing unilateral oophorectomy (UO) for benign indications, when compared to age-matched women with intact ovaries? SUMMARY ANSWER: A significantly reduced likelihood of future childbirth was observed in women with a history of UO, when compared to women with intact ovaries. WHAT IS KNOWN ALREADY: At the time of this study, the prevailing view is that a single ovary is sufficient to maintain fertility. This is the first large-scale observational study reporting an association between UO for benign indications and a decreased chance of future childbirth in a population-based cohort that was followed until the end of reproductive age. STUDY DESIGN, SIZE, DURATION: This population-based register study included all Swedish women born 1955–1966, followed until the end of female reproductive age. We identified 17 856 women who underwent UO (exposed) and 171 731 age-matched controls. After exclusions, the exposed cohort consisted of 10 469 women of fertile age with a benign indication for UO and 101 753 age-matched controls. PARTICIPANTS/MATERIALS, SETTING, METHODS: All cases of UO were identified by surgery codes and diagnosis of benign diseases, and up to 10 controls per case, matched by age and county, were used in the analysis. Childbirth data were collected from the Swedish Medical Birth Register, and childbirth rates were compared between exposed cases and age-matched controls. MAIN RESULTS AND THE ROLE OF CHANCE: The childbirth rate post-surgery was lower in women with UO compared to age-matched controls having intact ovaries: 25.5% versus 28.7%, respectively (risk ratio (RR) 0.89; confidence interval (95% CI) 0.86–0.91). Subgroup analysis of women who were nulliparous at the time of UO (N = 4083) versus their age-matched controls (N = 18 770) also indicated a lower childbirth rate: 41.3% vs 66%, respectively (RR 0.63; 95% CI 0.61–0.65). Additionally, an interaction analysis among the nulliparous women indicated that the reduced likelihood of having children was associated with older age at the time of UO. LIMITATIONS, REASONS FOR CAUTION: In this register-based study, the desire for pregnancy could not be captured, and it was unknown if it was similar among cases and controls. Although malignant indications of UO could be excluded in the study, the histopathology of the removed ovaries was not available; thus, it was not possible to adjust for specific diseases potentially affecting fertility, and therefore, residual confounding is a limitation. Additional limitations included the lack of adjustment for lifestyle factors, as such data was only available from the medical birth register, and thus only accessible for the women who had given birth. WIDER IMPLICATIONS OF THE FINDINGS: This large population-based study demonstrates a significant association between unilateral oophorectomy for benign indications and a reduced likelihood of subsequent childbirth; however, causality cannot be inferred from these observational data. STUDY FUNDING/COMPETING INTEREST(S): This work was funded by the Swedish Cancer Society (20 0170 F), the Swedish Research Council (Dnr 2021-06116 and Dnr 2023-01872), the Radiumhemmets Research Funds Grant for clinical researchers 2020–2026, the Childhood Cancer Fund (Dnr PR2022-0081), the Stockholm County Council (FoUI-953912) and the Karolinska Institutet Research grants Dnr 2020-01963 to K.A.R.W. The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The authors had full access to all study data and the final responsibility for the decision to submit for publication. K.A.R.W. has received: research grants from NovoNordisk, Merck, Gideon Richter and Ferring Pharmaceuticals; royalty for Student Literature (medical text book), Sweden; consulting fees from the Swedish Ministry of Health and Welfare as expert in assisted reproduction and fertility preservation for transgender people; consulting fees from SpringWorks; honoraria from Roche and Pfizer for chairmanship and lectures for education of oncologists; honoraria from Organon for lectures for ob/gyn and reproductive medicine specialists; and honoraria from IBSA for Advisory Board for educational events. K.AR.W. has also received support from Organon for participation in Journées Fertilité 2023, Paris, France, and support from Region Stockholm for participation as chair of the Swedish Interest Group in Reproductive Medicine Fert-ARG, for the Swedish Society of Obstetrics and Gynecology SFOG; participates at advisory board for Merck, Nordic countries, and on an advisory board for Ferring, National coordinator of study; and has received Time-lapse equipment for pre-clinical research from Merck pharmaceuticals and a grant for experimental in vitro research from Ferring Pharmaceuticals. The remaining authors have no conflicts of interest to declare. TRIAL REGISTRATION NUMBER: N/A